Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature

Table 3

Summary of publications with limited case-by-case information.

Reference	Patients with ILD	mTORi	Action mTORi	Outcome
Kidney transplantation
Baas et al. 2014 [55]	13	EVR	Disc.	Recovered
Bertolini et al. 2011 [56]	1	EVR	Not stated	Not stated
Champion et al. 2006 [57]	24	SRL	Disc.	Recovered
Errasti et al. 2010 [5]	8	SRL ( = 3) and EVR ( = 5)	Disc.	Recovered
Lee et al. 2012 [58]	12	SRL	Dose red. (4) and disc. (8)	Resolved
Morelon et al. 2000 [59]	3	SRL	Disc.	Resolved
Morelon et al. 2001 [60]	8^*	SRL	Dose red. (1) and disc. (7)	Resolved
Rodríguez-Moreno et al. 2009 [6]	6	SRL ( = 1) and EVR ( = 5)	Disc.	Recovered
Weiner et al. 2007 [61]	11	SRL	Dose red. (6) and disc. (5)	Resolved
Liver transplantation
Morcos et al. 2012 [62]	5	SRL	Disc.	Resolved
Roberts et al. 2007 [63]	4	SRL	Disc.	Resolved

Includes 3 cases described in Morelon 2000 [59] publication.
EVR, everolimus; Disc., discontinued; ILD, interstitial lung disease; mTORi, mammalian target of rapamycin inhibitor; SRL, sirolimus.